Olema Oncology Announces Preclinical Data for KAT6A Degraders
Olema Oncology reported preclinical data on its selective KAT6A degraders in ER+/HER2- breast cancer models, which will be presented at the 38th EORTC-NCI-AACR Symposium.
Stocks · News reference
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Olema Oncology reported preclinical data on its selective KAT6A degraders in ER+/HER2- breast cancer models, which will be presented at the 38th EORTC-NCI-AACR Symposium.
SOAR AI, Inc. (formerly Volato Group) announced a delay in filing its third-quarter 2026 financial results due to the complexities of accounting for its recent merger.
The Florida Department of Education has approved the 'Sadlier PreK with Wiley Blevins' curriculum for use by Voluntary Prekindergarten (VPK) providers on probation.
Filed: 2026-11-17 AccNo: 0001493152-26-052894 Size: 215 KB Item 4.01: Changes in Registrant's Certifying Accountant Item 9.01: Financial Statements and Exhibits
Scholar Rock Holding Corporation announced that its management team will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on December 1, 2026.
XORTX Therapeutics has finalized the manufacturing and packaging of its clinical drug supply for the upcoming XRX-OXY-102 clinical trial.